Digital PNG artwork · delivered by email | Secure checkout · no physical shipping
Hedi Raizer

Journal 6 min read

Melanotan II: reported timelines in the literature

A research-supply overview of reported timelines for Melanotan II, covering case reports, trial records, and preclinical models. For laboratory research use only.

peptides-pro Editorial

Melanotan II (MT-II) is a synthetic peptide analog belonging to the melanocortin hormone family, also referred to in the literature as melanotan II, MT-II, or by the informal term 'Barbie drug' in forensic contexts [1][5]. It is an unlicensed compound, and its sale is illegal in some jurisdictions [3]. The evidence block does not provide a sequence, molecular formula, or molecular weight for Melanotan II. The work described here centres on the melanocortin receptor family, a group of Class A G protein-coupled receptors (GPCRs) that includes five subtypes (MC1R–MC5R), with Melanotan II acting primarily at melanocortin 1 receptors on melanocytes [1][6].

Reported timelines in the literature vary by context. A case report followed a patient for three months after self-administered injections over 64 days [1]. A registered Phase 2 trial record describes Melanotan II as an adjunct to NB-UVB phototherapy in adults with stable nonsegmental vitiligo [2]. Preclinical work in male rats has examined behavioural and stress-axis endpoints [4]. Forensic analyses have identified the compound in submitted powder samples [5]. Each of these represents a different model or population, and the timelines reported are specific to those settings.

Research Studies

Melanotan II and oral mucosal pigmentation in a case report

A case report documented changes in the oral mucosa of a patient who self-administered Melanotan II injections over 64 days with the goal of achieving a deeper tanning effect [1]. The report presents a three-month follow-up. During the initial intraoral examination, brown pigmentation was observed [1]. The authors note that Melanotan II acts primarily by activating melanocortin 1 receptors on melanocytes, stimulating eumelanin production and resulting in skin pigmentation independent of sun exposure [1]. The report also states that Melanotan II remains unregulated and that its use is associated with a range of potential adverse effects [1]. This is a single-patient observation; it does not establish incidence or a general timeline for mucosal changes.

Melanotan II and repigmentation in stable nonsegmental vitiligo: a trial record

A ClinicalTrials.gov record describes a randomized Phase 2 interventional study evaluating investigational Melanotan II (MT-II) as an adjunct to standard NB-UVB phototherapy for repigmentation in adults with stable nonsegmental vitiligo [2]. The record identifies the population as adults with stable nonsegmental vitiligo and the intervention as MT-II added to NB-UVB [2]. No results, duration, or outcome data are provided in the evidence block. The existence of this record indicates that a controlled clinical timeline has been proposed for this indication, but the evidence block does not report what that timeline was or what was observed.

Melanotan II and oral mucosal malignant melanoma: a case report

A separate case report describes a 22-year-old female who developed a mass in the anterior maxilla after using a Melanotan II nasal spray for tanning purposes [3]. The report characterises the product as a nasal spray containing a synthetic analogue of melanocyte-stimulating hormone and notes that Melanotan II is unlicensed and its sale is illegal in the United Kingdom [3]. This is a single case and is marked REFERENCE ONLY in the evidence block; it supports the broader literature on reported adverse events but does not provide a timeline or incidence figure.

Melanotan II and antidepressant-like effects in male rats under chronic unpredictable stress

A preclinical study examined the ACTH(4-10) synthetic analogs Semax and Melanotan II in male rats using a model of chronic unpredictable stress [4]. The report notes that stressful events and hyperactivity of the hypothalamic-pituitary-adrenal (HPA) axis play an important role in the pathogenesis of depression, and that current antidepressant therapy has substantial limitations [4]. The study is animal-only; the evidence block does not provide dosing, duration, or effect sizes. Findings in male rats under a chronic unpredictable stress model cannot be extrapolated to humans.

Melanotan II and forensic identification in submitted samples

A forensic analysis described the identification of various samples, including two vials with a pharmaceutical appearance, submitted to a laboratory [5]. The aim was to describe the unique characteristics observed during analysis of the powder contained in the vial [5]. Samples were subjected to HPLC-DAD, UHPLC-TOF-MS, and/or UPLC-MS-MS [5]. This work is analytical and does not report biological timelines or effects. It is marked REFERENCE ONLY and supports the page by documenting that Melanotan II has been detected in real-world samples submitted for identification.

Melanotan II and melanocortin receptor tool compounds

A review of recommended tool compounds for the melanocortin receptor (MCR) family describes these receptors as a centrally and peripherally expressed family of Class A GPCRs with physiological roles including pigmentation, steroidogenesis, and energy homeostasis [6]. There are five melanocortin receptor subtypes, apart from the melanocortin-2 receptor (MC2R) [6]. Melanotan II is referenced in this context as a synthetic analog within the melanocortin family [1][6]. This source is marked REFERENCE ONLY and provides receptor-family background rather than a timeline.

Melanotan II and reported timelines: what the evidence does and does not show

The evidence block does not provide a consolidated timeline for Melanotan II across studies. The case report offers a 64-day self-administration period with a three-month follow-up [1]. The trial record describes a Phase 2 design in adults with stable nonsegmental vitiligo but does not report duration or outcomes [2]. The preclinical study in male rats does not report a timeline in the evidence block [4]. The forensic analysis reports sample identification, not a biological timeline [5]. The receptor review provides no timeline [6].

SourceModel or populationReported timeline
[1] Case reportSingle patient, self-administered injections64 days of use; 3-month follow-up
[2] Trial recordAdults with stable nonsegmental vitiligoNot reported in evidence block
[3] Case report22-year-old female, nasal spray useNot reported in evidence block
[4] Preclinical studyMale rats, chronic unpredictable stressNot reported in evidence block
[5] Forensic analysisSubmitted powder samplesNot applicable
[6] Receptor reviewIn vitro / pharmacological characterisationNot applicable

Melanotan II and the limits of the current evidence

Across the sources in the evidence block, the only explicit timeline is the 64-day self-administration period with a three-month follow-up in a single case report [1]. The Phase 2 trial record establishes that a controlled study has been registered in adults with stable nonsegmental vitiligo, but no results are available in the evidence block [2]. The preclinical study is animal-only and does not report a timeline in the evidence block [4]. The forensic and receptor-review sources are REFERENCE ONLY and do not contribute timeline data [5][6]. No source in the evidence block provides a dose, a schedule, or a comparative timeline across subjects.

Melanotan II and the importance of model context

The evidence block spans a single-patient case report [1], a registered trial record [2], a second case report [3], a rat study [4], a forensic analysis [5], and a receptor review [6]. Each of these represents a different level of evidence. The case reports describe individual outcomes and cannot be used to estimate frequency or typical timelines [1][3]. The trial record describes a planned study, not completed results [2]. The rat study is animal-only [4]. The forensic and review sources are REFERENCE ONLY and provide context rather than primary timeline data [5][6]. Any statement about how long effects take to appear or resolve in humans would require evidence not present in this block.

If you are reading this for personal health reasons

This material is sold for laboratory research only. We do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician.

Sources

WhatsApp